Celltrion’s COVID-19 antibody treatment applies for use in Korea
Treatment to be available in Korea from Feb., overseas applications to be filed in Jan. |
Celltrion’s CT-P59, also known as regdanvimab (Celltrion)
Local biologics company Celltrion on Tuesday filed for approval of its COVID-19 antibody treatment for use here, in what Seoul officials hope will be a new weapon in the country’s war against the new coronavirus in the absence of vaccines.
The Drug Ministry said it will attempt to review the safety and efficacy of the proposed COVID-19 treatment in the next 40 days.
If approved, the drug is anticipated to be ready for use in February in Korea.
Will COVID-19 treatment be Celltrion founder’s retirement legacy?
Results of phase 2 clinical trial of coronavirus antibody agent set to be unveiled |
Celltrion logo (Celltrion)
Late on the front of coronavirus vaccine development and procurement, South Korea is pinning hopes on one particular company to provide the much-needed relief in this dark, pandemic winter Celltrion.
The company is expected to announce in coming days results of its global clinical phase 2 trial of an anti-COVID-19 monoclonal antibody treatment candidate, CT-P59.
Celltrion’s media-friendly founder and chairman Seo Jung-jin has said plenty of times that its drug, if approved, would “put an end” to the country’s struggles with the deadly virus.
Businesses brace for near shutdown
Retailers to suffer the most; exporters likely to be spared from restrictions |
The image shows the street of Myeongdong, one of Seoul s most visited tourist spots, on Dec. 8. (Yonhap)
As South Korea’s daily coronavirus tally rose to a new record on Sunday, local businesses are bracing for a possible upgrade in the country’s social distancing rules to the toughest level yet – a partial shutdown.
While Level 3 of the government-set five-tier social distancing scheme is expected to decimate conventional retail industries, export-driven sectors such as mobile phones and semiconductor chips are less likely to be massively affected, experts and industry insiders said.
SK Innovation reiterates Georgia plant benefits US economy |
How SK Innovation s Georgia plant will look upon construction completion (SK Innovation)
SK Innovation’s aggressive battery investments have trickle-down effects for local businesses in Korea and the US, the Korean firm claimed Friday, as it sought to burnish its contributions to the economy ahead of a lawsuit ruling in the US.
The energy firm is currently building two electric battery plants in the US state of Georgia. The first of those, with capacity of 9.8 GWh of production a year, is expected to be finished and start test runs next year. It is due to enter full-fledged operation in early 2022.
Lemonex wins Innovation Winner 2020 with DegradaBALL |
Lemonex’s chief technology officer Min Dal-hee presents at the 2018 mRNA Healthcare Conference (Lemonex)
Lemonex, a South Korean biotherapeutics and biotech company, was acknowledged with an Industry and Energy Ministerial prize for technology innovation at the Innovation Winner 2020 awards.
The Innovation Winner 2020 was hosted by Herald Corp. in collaboration with monthly magazine PowerKorea on Thursday.
Lemonex won for its original drug delivery technology called DegradaBALL.
“DegradaBALL enables effective delivery of various new drug candidates into cultured cells or lesions by loading the drugs inside,” said Won Cheol-hee, chief executive officer of Lemonex.
“It is a next-generation drug delivery technology optimized especially for the development of gene therapy, cancer immuno-therapy, antibody therapy, and synthetic drugs,” said Won.